Breaking Down Biosimilar Insulins: A Look at the Regulatory Process and Impacts

Host: John Buse, MD, PhD Guest: Simon Heller, MD Amid the crisis around the cost of diabetes care worldwide, biosimilar insulins could help save millions of dollars and allow more patients to be treated safely and effectively. But how exactly are these products approved, and how do they compare to the original product? Find out with Dr. John Buse and Dr. Simon Heller, Professor of Clinical Diabetes at the University of Sheffield and the Director of Research and Development at Sheffield Teaching Hospitals Foundation Trust in the United Kingdom. Together, they’ll review Dr. Heller’s recent paper on biosimilar basal insulins that was published in Clinical Diabetes.

You can listen to Breaking Down Biosimilar Insulins: A Look at the Regulatory Process and Impacts online on Radio and Podcast. Open the player on this page to stream the available audio.

Breaking Down Biosimilar Insulins: A Look at the Regulatory Process and Impacts is an episode from Diabetes Discourse by ReachMD.

This episode is 00:11:30 long.

This episode was published on Oct 25, 2023.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Diabetes Discourse when more episodes are available from the podcast feed.